Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISLEND-1
2024-514046-37-00Phase 3Authorised
- Sponsor
- Gilead Sciences
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of islatravir + lenacapavir in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Gilead Sciences. Primary endpoint: Proportion of participants with HIV-1 RNA ≥ 50 copies/mL at Week 48. Planned start Dec 2024; status: authorised.
02
Drugs
islatravir + lenacapavir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2024-514046-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514046-37-00.